QQQ

DIA

SPY

TLT

GLD

BTC/USD

QQQ

DIA

SPY

TLT

GLD

BTC/USD

Range

10.65 - 10.95

Vol / Avg.

373.1K/773.7K

Div / Yield

-

52 Wk

8.58 - 16.73

Mkt Cap

781.3M

Payout Ratio

-

Open

10.95

P/E

120.89

EPS

-0.02

Shares

72M

Outstanding

72M

Total Float

60.1M

Analyst Ratings

White House COVID-19 Coordinator Zients Says U.S. Making Further $1B Investment In Testing To Buy Additional 180M Tests

Benzinga - Oct 6, 2021, 3:11PM

White House Advisor ZIents Says Quidel, OraSure Are Further/More Rapidly Expanding Production Of Their Tests To Get More Capacity Of The Market

Benzinga - Oct 6, 2021, 3:10PM

OraSure Wins $109M Contract To Increase COVID-19 Test Manufacturing Capacity

Benzinga - Oct 4, 2021, 3:39PM

OraSure Technologies shares are trading higher after the company won a $109M Department of Defense contract to manufacture COVID-19 tests.

Benzinga - Oct 4, 2021, 7:40AM

OraSure Wins $109M Department of Defense Contract to Manufacture a COVID-19 Rapid Test

Benzinga - Oct 4, 2021, 7:07AM

FDA Establishes Additional Conditions Of Emergency Use Nod For COVID-19 Tests For Viral Mutations

Benzinga - Sep 24, 2021, 1:21PM

OraSure Secures $13.6M BARDA Funding For InteliSwab COVID-19 Test 510(k) Clearance and CLIA Waiver

Benzinga - Sep 23, 2021, 10:00AM

OraSure Technologies Reports Will Receive U p To $13.6M From Biomedical Advanced Research Development Authority To Support InteliSwab COVID-19 Rapid Test 510(k) Clearance, Clinical Lab Improvement Amendments Waiver

Benzinga - Sep 23, 2021, 8:11AM

Raymond James Downgrades OraSure Technologies to Market Perform

Benzinga - Sep 22, 2021, 5:03AM

OraSure Secures $205M Contract For OTC COVID-19 Tests

Benzinga - Sep 20, 2021, 6:54AM

OraSure Receives $205M Procurement Contract For InteliSwab From The Defense Logistics Agency To Supply Over-The-Counter Kits As Part Of National Pandemic Response

Benzinga - Sep 20, 2021, 6:02AM

OraSure Technologies shares are trading higher. Raymond James said the company won a $512 million contract.

Benzinga - Sep 17, 2021, 2:52PM

OraSure Technologies Shares See Volume; Raymond James Says Co Wins $512M Contract

Benzinga - Sep 17, 2021, 1:07PM

OraSure Technologies Announces Resignation Of CFO Roberto Cuca; Co. Has Initiated Search For Permanent CFO

Benzinga - Sep 2, 2021, 7:06AM

OraSure Stock Is Trading Lower As Q2 Earnings, Outlook Trail Estimates

Benzinga - Aug 4, 2021, 11:27AM

OraSure Technologies shares are trading lower after the company reported worse-than-expected Q2 EPS results and issued Q3 and FY21 sales guidance below estimates.

Benzinga - Aug 4, 2021, 8:19AM

Raymond James Maintains Outperform on OraSure Technologies, Raises Price Target to $12.5

Benzinga - Aug 4, 2021, 7:34AM

OraSure Technologies shares are trading lower after the company reported worse-than-expected Q2 EPS results and issued Q3 and FY21 sales guidance below estimates.

Benzinga - Aug 3, 2021, 4:49PM

OraSure Technologies Sees Q3 Sales $45M-$50M Vs. $67.88M Est., FY21 Sales ~$230M Vs. $287.63M Est.

Benzinga - Aug 3, 2021, 4:45PM

OraSure Technologies Q2 EPS $(0.02) Misses $0.04 Estimate, Sales $57.61M Beat $56.69M Estimate

Benzinga - Aug 3, 2021, 4:44PM

load more

Sector: Health Care.Industry: Health Care Equipment & Supplies

OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.

Earnings

Q3 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-11-08
REV		(EXPECTED)2021-11-08

Q2 2021		Est.		Actual		Surprise
EPS		0.040		-0.020		-0.0600
REV		56.690M		57.607M		917.000K

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

OraSure Technologies Questions & Anwsers

Q

How do I buy OraSure Technologies (OSUR) stock?

A

You can purchase shares of OraSure Technologies (NASDAQ: OSUR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are OraSure Technologies's (OSUR) competitors?

A

Other companies in OraSure Technologies’s space includes: Meridian Bioscience (NASDAQ:VIVO), SI-BONE (NASDAQ:SIBN), BioLife Solutions (NASDAQ:BLFS), ICU Medical (NASDAQ:ICUI) and Align Tech (NASDAQ:ALGN).

Q

What is the target price for OraSure Technologies (OSUR) stock?

A

The latest price target for OraSure Technologies (NASDAQ: OSUR) was reported by Raymond James on September 22, 2021. The analyst firm set a price target for 0.00 expecting OSUR to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for OraSure Technologies (OSUR)?

A

The stock price for OraSure Technologies (NASDAQ: OSUR) is $10.85 last updated Mon Oct 25 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Q

Does OraSure Technologies (OSUR) pay a dividend?

A

There are no upcoming dividends for OraSure Technologies.

Q

When is OraSure Technologies (NASDAQ:OSUR) reporting earnings?

A

OraSure Technologies’s $Q3 earnings are confirmed for after-market on $November 8, 2021.

Q

Is OraSure Technologies (OSUR) going to split?

A

There is no upcoming split for OraSure Technologies.

Q

What sector and industry does OraSure Technologies (OSUR) operate in?

A

OraSure Technologies is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.